News
Click here to subscribe to our news updates
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
August 26, 2025 | Company Announcements
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira August 26, 2025 | Company Announcements
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%August 22, 2025 | Company Announcements
Bavarian Nordic Announces First Half 2025 ResultsJuly 31, 2025 | Company Announcements
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial GuidanceJuly 28, 2025 | Company Announcements
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian NordicJuly 24, 2025 | Company Announcements
Rumours of a Potential Takeover Offer for Bavarian Nordic A/SJuly 22, 2025 | Press Releases
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya VaccineJuly 09, 2025 | Company Announcements
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European CountryJune 26, 2025 | Press Releases
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women June 18, 2025 | Company Announcements
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 MillionJune 12, 2025 | Press Releases
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in ChildrenMay 09, 2025 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2025May 06, 2025 | Company Announcements
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox VaccinesMay 02, 2025 | Press Releases
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United KingdomApril 16, 2025 | Company Announcements
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)April 09, 2025 | Company Announcements
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/SMarch 31, 2025 | Company Announcements
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine March 12, 2025 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General Meeting March 07, 2025 | Press Releases
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and OlderMarch 05, 2025 | Company Announcements
Bavarian Nordic Publishes Annual Report 2024February 28, 2025 | Company Announcements
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and OlderFebruary 25, 2025 | Press Releases
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine February 14, 2025 | Company Announcements
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and OlderFebruary 03, 2025 | Company Announcements
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025January 31, 2025 | Company Announcements
Bavarian Nordic – Completion of Share Buy-Back Program